Available Grant Opportunities

Week of Mar. 27th-31st, 2017

Check back often for weekly updates

 

Internal Funding Opportunities

University of Michigan Office of Research, MIDAS, and DiDi - Machine Learning; Behavioral Economics; Operational Research; and Public Transit Optimization grants ($150,000 award, pre-proposal deadline April 14th).  The University of Michigan Office of Research, MIDAS and DiDi are pleased to announce a call for proposals in the areas of machine learning; behavioral economics; operational research; and public transit optimization. Proposals are open to all faculty and research scientists. Depending on project size and scope, DiDi generally expects to fund 6-8 one-year proposals at UM for ~$150,000 each. Proposals will be eligible for an additional 1-2 years of funding, pending the meeting of mutually agreed-upon milestones. April 14: Pre-proposals due to midas-rfp@umich.edu - for questions, please contact midas-rfp@umich.edu, Amy Klinke (amyklink@umich.edu) or Christine Muchanic (muchanic@umich.edu).

Limited Submission Opportunity - 2017 V Foundation V Scholar Award ($200,000 award, deadline April 13th, 2017).  The V Foundation seeks to support young tenure-track faculty early in their cancer research career by funding projects that are either laboratory-based fundamental research or translational research. The total amount of the grant is $200,000 awarded in two annual installments of $100,000. Only direct costs of the research are supported by this award. The U-M Comprehensive Cancer Center may nominate two applicants if at least one of the two applicants two nominee applicants identifies as someone from an underrepresented in science minority ethnic group (for the Applicant Eligibility: All nominated applicants must meet all of the following criteria to be eligible to submit an application: Applicant must by nominated by the Cancer Center Director.  Applicant must have at least 2 years post-doctoral (MD or PhD) fellowship training. For MDs, a minimum of one year is acceptable if only one year is required for the specialty.  By the Due Date of the Application, applicants must have all the following: Hold a tenure-track faculty position as an assistant professor at their cancer research institution. Non-promotable, adjunct, affiliated, temporary, part-time or acting faculty positions are not eligible for this grant competition; Have been appointed to their first full-time assistant professor position within the last 5 years, and not yet been promoted to Associate Professor;  Clinical scientists are eligible if the research institution can demonstrate that it will fully support the research applicant (e.g., dedicated lab space, start-up funds, dedicated research time); Applicants must be either US Citizens or be a permanent legal resident in the US; and, Applicant can NOT already have been awarded an RO1 or RO1-equivalent grants. Internal Deadline: April 13, 2017 at 5:00 PM, Letter of Intent Deadline: May 1, 2017 at 5:00 PM, V Scholar Application Date: June 1, 2017 at 5:00 PM. Institutional Nominees Allowed: 2. Sponsor Website: https://www.jimmyv.org/ Research Area(s):  Any area of cancer research is permitted.  Please contact Kimberly Zuhlke at 734‑647‑7222 or (kzuhlke@umich.edu) with any questions.

External Funding Opportunities:

Leukemia & Lymphoma Society - Mantle Cell Lymphoma Research Initiative ($2.5 Million award, deadline May 15th, 2017).  Supports teams of researchers representing different disciplines and engaged in collaborative efforts to discover new approaches to treat patients with blood cancers. The Leukemia & Lymphoma Society (LLS) announces a competitive grant program to benefit mantle cell lymphoma (MCL) patients. This is a milestone-driven research program with an overarching goal to move discoveries quickly from the bench to the clinic. this is a milestone-driven research program with an overarching goal to move discoveries quickly from the bench to the clinic. The program is intended to bring together at least 3 independent research projects that are integrated and supported by scientific cores. Inter-institutional or intra-institutional synergistic collaborations to greatly advance research progress and clinical application are expected. Award: LLS will award up to 2 new awards to improve therapies for MCL. The application will be reviewed by a panel of peers including experts in the field of MCL. Applications will be accepted from non-profit and profit organizations. Importantly, the research grants must be supported by a matching contribution from another source. While ideally the matching contribution will be equal to the award ($2.5 million from LLS and $2.5 million or its equivalent from another source), a matching contribution with a minimum value of $ 1.25 M will be considered. The qualified matching contribution may include, but is not limited to, cash, equipment purchases, salary support for personnel, waiving of institutional indirect costs (up to 20% of the funds supplied by this grant), Pharma funding for novel clinical trial (e.g. drug, patient) costs, or other resources (e.g. patient samples or use of core facilities). The application of institutional resources towards the matching contribution must be either new efforts or extend work already underway and cannot overlap with current grants. Each MCL-RI is comprised of a minimum of three scientific Projects and a minimum of two scientific Cores that will cooperate under the leadership of an MCL-RI Director. There must be objective evidence of interdisciplinary research among the Projects and Cores. Letter of Intent Deadline: May 15, 2017 3:00 PM ET.

Ovarian Cancer Research Fund Alliance - multiple opportunities:
Collaborative Research Development Grant ($900,000 award, Letter of Intent deadline April 28th, 2017).  This grant program provides funds for large ovarian cancer research projects that involve several investigators within one institution or collaborations between groups in multiple institutions. The grant is for investigators seeking to develop program project grant applications for submission to peer-review funding agencies (e.g. NCI, RO1, SPORE, DOD). Support of $300,000 annually for three years will be awarded to the institution(s) in which the recipients will conduct the research. OCRFA is currently accepting letters of intent through April 28, 2017.

Liz Tilberis Early Career Award ($450,000 award, Letter of Intent deadline April 28th, 2017).  Launched in December 2000, the Liz Tilberis Early Career Award is for junior faculty with a strong commitment to an investigative career in ovarian cancer research. These awards support a substantial time commitment to research and academic endeavors in ovarian cancer. Each grantee will receive a three-year grant of $150,000 per year. OCRFA is currently accepting letters of intent through April 28, 2017.

Ann and Sol Schreiber Mentored Investigator Award ($75,000 award, Letter of Intent deadline April 28th, 2017).  The Ann and Sol Schreiber Mentored Investigator Award provides funding for trainees who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research. Applicants must be clinical fellows (Gynecologic Oncology, Medical Oncology), or post-doctoral fellows. Candidates for this program must have an MD or a PhD degree. The award provides a total of $75,000 to be used over one or two years, and will encourage the recipient’s research career in the field of ovarian cancer.

Damon Runyon Cancer Research Foundation - two opportunities:
Damon Runyon-Rachleff Innovation Award ($600,000 award, deadline July 6th, 2017).  The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. The Stage 1 award will be for two years, $150,000 per year ($300,000 total) with the opportunity for up to two additional years of funding (up to four years total for $600,000). Stage 2 support for years three and four will be granted to those awardees who demonstrate progress on their proposed research during years one and two of the award. Applicants will provide a written update on their research and present their progress in person to the committee shortly before the end of the second year of the award, at which time the committee will make a decision regarding continued funding.

Damon Runyon Fellowship ($231,000 award, deadline August 15th, 2017).  The Foundation encourages all theoretical and experimental research relevant to the study of cancer and the search for cancer causes, mechanisms, therapies and prevention. Candidates must apply for the fellowship under the guidance of a Sponsor—a scientist (tenured, tenure-track or equivalent position) capable of providing mentorship to the Fellow. In addition to aiding in the planning, execution and supervision of the proposed research, the Sponsor’s role is to foster the development of the Fellow’s overall knowledge, technical and analytical skills, and capacity for scientific inquiry. The Sponsor is also expected to assist the Fellow in attaining his/her career goals. Awards are made to institutions for the support of the Fellow under direct supervision of the Sponsor. Candidates who have already accepted a postdoctoral research fellowship award are not eligible. Damon Runyon Postdoctoral Research Fellowships are granted for a four-year term with second, third- and fourth- year funding contingent upon satisfactory progress reports. Fellows in their first and third years of funding will attend Damon Runyon Fellows' Retreats designed to foster collaboration and interaction between scientists working in different fields relevant to cancer. Award Stipends:
            Stipend                       Expenses
            Year 1 $52,000           $2,000
            Year 2 $54,000           $2,000
            Year 3 $57,000           $2,000
            Year 4 $60,000           $2,000

Progeria Research Foundation - Request for Proposals ($300,000 award, deadline September 19th, 2017).  PRF is seeking proposals that address the following priorities: 1) Discovery of biological markers of disease in HGPS that can be assessed in human and/or mouse samples. Highest priority will be given to those markers that can be assayed in easily obtainable human samples such as blood, urine, and cheek swabs. In addition, proposals that explore biomarker relevance to disease process and /or change in markers with disease treatment are encouraged. 2) Discovery and/or testing of candidate treatment compounds in both cell based and mouse models of HGPS. Of note, proposals should test compounds in a progerin-producing mouse model as the priority. Comparisons to other mouse models of disease, such as ZMPSTE24 -/- and other non-progerin producing mouse models are acceptable, but only as a comparison to progerin-producing models. 2017 Deadline: September 19, 2017 for consideration at the December 2017 Board of Directors Meeting.

Lipedema Foundation Grant Programs ($250,000 award, Letter of Intent deadline May 15th, 2017).   We encourage applicants to submit proposals that align with the Foundation's Mission, Strategy, and Values. Mission: To Define, Diagnose, and Develop Treatments for Lipedema.  Strategy: The Lipedema Foundation supports collaborative research that addresses the basic biology, genetics, and epidemiology of lipedema.  Values: Transparency, the Foundation strives for an open and active discussion with and amongst grantees.  Collaboration, the Foundation stresses the importance of collaborative research.  Community, the Foundation favors research efforts that will build and leverage a patient-researcher community.  Funding Programs: As the lipedema research field remains to be defined, we request that single and multi-year applications be milestone-driven. The listed programs are meant to be guidelines for applicants, and the Foundation welcomes applications that may involve more flexibility. Collaborative Research Award - Designed to foster collaborative research, these awards offer a longer time horizon to accomplish proposed research and requires involvement of multiple institutions or multi-disciplinary researchers. Maximum award, $250,000, applicable towards proportional salary, fringe benefits, and research costs.  Duration, two years, milestone driven award.  Applications that involve current Foundation grantees receive priority review. Proof-of-Concept Award - Designed for early stage and established investigators with research hypotheses with potential relevance to lipedema. Maximum award, $125,000, applicable towards proportional salary, fringe benefits, and research costs. Duration, one year.  Grantees are eligible for a streamlined renewal process.   Post-doctoral Fellowship -Designed for post-docs at any stage of their training.  Maximum annual award/stipend, $50,000.  Duration, two years guaranteed, third year renewable. Highly qualified applications are eligible for up to $25,000 in independent research funding. Pre-doctoral Fellowship - Designed for graduate students at any stage of their training. Maximum annual stipend, $25,000. Duration, two years guaranteed, third year renewable. Highly qualified applications are eligible for up to $10,000 in independent research funding. The Lipedema Foundation welcomes Letter of Intent submissions until May 15, 2017.

Pfizer - Patient Education in Advanced or Metastatic Breast Cancer Treatment ($250,000 award, deadline May 23rd, 2017).  It is our intent to support patient education programs designed to advance patient understanding of advanced or metastatic breast cancer and improve their ability to make informed decisions about their care.  Educational initiatives may include: Disease information including factors that influence treatment decisions (i.e. disease specific, treatment specific); Information on current treatment options; Increasing access to clinical trials, in particular, those with a focus on diversity and inclusion; Patient and care giver support programs; and, Guides for patients on how to have a meaningful discussion with their physician about their own treatment (e.g. taking into consideration the needs and goals of patients, building the patient’s understanding of what is likely to occur, and aligning the expectations of both patients and physicians).  Educational programs should be designed for patients, their caregivers, and their families. Proposals for this CGA should not include healthcare provider training or professional education.  All activity types (e.g. live, print, online, mobile applications) will be considered through this CGA, but we are particularly interested in innovative, technology-enabled solutions that will help patients living with advanced or metastic breast cancer increase their understanding of and participation in their care plan. Efforts should be made to encourage interaction, incorporate case-based discussions, and/or provide opportunities to extend and reinforce learning. Individual projects requesting up to $250,000 will be considered, however, the expected range of proposals to this CGA is from approximately $20,000 to $125,000.

Johnson & Johnson - Advancing the Safe Use of Healthcare Products QuickFire Challenge ($200,000 award, deadline May 24th, 2017).  The Challenge: Johnson & Johnson’s Office of the Chief Medical Officer (OCMO) works to ensure that the safety data underpinning all our product are scientifically sound and robust; following from that, it is also an OCMO priority to provide healthcare practitioners, physicians, surgeons, patients and consumers with the most informative data and understanding of the safety of our products so that they may make well informed healthcare decisions. To that end, Johnson & Johnson Innovation and the OCMO are looking to reward up to $200,000 in multiple grants, and one year of JLABS space, to the individuals or teams who submit the best ideas on how to educate, inform and provide clarity around healthcare product safety. QuickFire Challenge innovation focus areas: Empowering patients and consumers to make more informed healthcare decisions by providing better information and education about the safety of healthcare products (pharmaceuticals, medical devices and consumer products). Improving training and development for surgeons by identifying new models that simulate the operating room environment. Empowering patients and consumers to more safely administer and handle healthcare products. Rewards and benefits: Up to $200,000 USD in grants for multiple winners. Entrance to an available JLABS. Mentoring & Coaching.  

Myositis Association - Research Funding ($150,000 award, Letter of Intent deadline May 15th, 2017).  The Myositis Association is pleased to be able to offer funding for research into any type of immune-mediated myositis. Fellowship funding is available for $50,000 per year for 2 years, and grant funding is available for a maximum of $75,000 per year for 2 years.
Research Fellowships – to support a young physician, or PhD scientist, who is beginning a career in myositis research in the laboratory of an established myositis investigator. Research Grants – to support new or innovative myositis research projects.

Social Interventions Research and Evaluation Network (SIREN) - Call for Proposals ($150,000 award, Email of Intent to Apply due May 15th, 2017).  The Social Interventions Research and Evaluation Network (SIREN) was created in 2016 to catalyze and disseminate high quality research on how to address patients’ basic resource needs as part of high quality clinical care. To advance these goals, SIREN’s Innovation Grants program will support research projects that advance work in this area. Our first Call for Proposals focuses on projects that add to our understanding of the health care cost and utilization impacts of interventions initiated in the context of health care delivery that target patients’ social and economic hardships.  Innovation Grant Details: SIREN seeks applications for research projects that will contribute rigorous evidence about health care cost and/or utilization impacts of clinical interventions addressing patients’ social and economic hardships. This Call for Proposals is specifically designed to fund studies that: 1) examine the impact of these interventions on health care costs and/or utilization; 2) include cost-benefit analyses comparing the economic impacts of the interventions to their implementation costs; or 3) conduct cost-effectiveness analyses comparing the costs of different social and economic needs interventions. Our aim is to fund approximately 3 to 6 applications from a total pool of $530,000, with a maximum grant award of $150,000. In making funding decisions, we will balance the desirability of maximizing the number of awards with the goal of supporting high impact and high quality research and projects that lay the groundwork for such research. Recognizing that diverse perspectives strengthen research, especially research with populations experiencing social and economic hardships, we encourage applicants from underrepresented backgrounds to apply. The application deadline for this funding opportunity is June 15, 2017 at 5:00pm PDT. Interested applicants must signal their intent to apply by sending an email to siren@ucsf.edu by May 15, 2017 at 5:00pm PDT.

Gilead Sciences - multiple opportunities:
Research Scholars Program in Cardiovascular Disease ($130,000 award, deadline July 7th, 2017).  The mission of the Gilead Sciences Research Scholars Program in Cardiovascular Disease is to support innovative scientific research that will advance knowledge in the field of cardiovascular disease. Gilead Sciences, Inc. expects that the research supported by these awards will enhance understanding of cardiovascular disease and develop the careers of early stage investigators. The Program provides financial support to 3 junior faculty researchers for a 2-year period. Each award is funded up to $130,000 (inclusive of any indirect costs), to be paid in annual installments of up to $65,000 per year for 2 years. Funding for the second year is contingent upon submission of a progress report and approval by the Scientific Review Committee Chair. The Program is designed to support basic and clinical research in the field of cardiovascular disease. Submission Deadline: Friday, July 7, 2017, Midnight, Eastern Daylight Time.

Research Scholars Program in Cystic Fibrosis ($130,000 award, deadline July 21st, 2017).  The mission of the Gilead Sciences Research Scholars Program in Cystic Fibrosis is to support innovative scientific research that will advance knowledge in the fields of pediatric and adult cystic fibrosis and provide support for early research career development. Gilead Sciences, Inc. hopes that the research supported by these awards will enhance understanding of cystic fibrosis. The Program is designed to support basic, translational, and clinical research in the field of cystic fibrosis. Areas of research may include, but are not limited to: CF basic pathophysiology; CF-specific microbiology; and, CF-related epidemiology, clinical care, and health-related outcomes. The Program provides financial support to 3 junior faculty researchers for a 2-year period. Each award is funded up to USD130,000, to be paid in annual installments of up to USD65,000 per year for 2 years. Funding for the second year is contingent upon submission of a progress report and approval by the Scientific Review Committee Chair. Submission Deadline: Friday, July 21, 2017, Midnight, Eastern Daylight Time.

Research Scholars Program in Pulmonary Arterial Hypertension ($130,000 award, deadline August 4th, 2017).  The mission of the Gilead Sciences Research Scholars Program in Pulmonary Arterial Hypertension (PAH) is to support innovative scientific research that will advance knowledge in the field of pulmonary arterial hypertension, or PAH. Gilead Sciences, Inc. hopes that the research supported by these awards will enhance understanding of pulmonary arterial hypertension. The Program provides financial support to 3 junior faculty researchers for a 2-year period. Each award is funded up to $130,000, to be paid in annual installments of up to $65,000 per year for 2 years. Funding for the second year is contingent upon submission of a progress report and approval by the Scientific Review Committee Chair. The Program is designed to support basic science and clinical research in the field of pulmonary arterial hypertension. Areas of research may include, but are not limited to: Basic science underlying PAH; Genetics of PAH; Pathophysiology of PAH; Epidemiology of PAH; and,Techniques for early diagnosis of PAH. The Program is designed to support new original research. Proposals with significant scientific overlap with funded research projects from a peer review agency or industry source will not be considered. Submission Deadline: Friday, August 4, 2017, Midnight, Eastern Daylight Time.

Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium - Funding Opportunity for Pilot and Feasibility Studies ($100,000 award, deadline June 19th, 2017).  The Scientific and Data Coordinating Center (SDCC) for the Prevention of Lower Urinary Tract Symptoms (PLUS) in Women Research Consortium, supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), invites research grant applications to conduct pilot and feasibility studies that support the mission of the PLUS Consortium, which is to identify promising strategies for promoting bladder health and reducing lower urinary tract symptoms and conditions in women throughout the lifespan. The purpose of this announcement is to solicit grant applications for pilot and feasibility studies to increase our understanding of risk and protective factors important for promoting bladder health and preventing LUTS in women across the entire lifespan. Applicants are encouraged to propose studies that will add value to the PLUS Consortium’s goal to understand the spectrum of bladder health and risk and protective factors among women and girls in the general population. These include biological, social, and psychological factors that can be explored as influencing bladder health across the lifespan. Applications must describe how proposed studies address the PLUS Consortium goals of informing future LUTS prevention intervention studies. Basic science, clinical (qualitative and quantitative) and epidemiologic studies that can be accomplished within the allowed budget are considered in scope for this funding opportunity. Studies proposing the use of innovative methods and technical approaches are encouraged, though not required. Studies that propose using available resources developed by clinical science or epidemiologic studies to address questions relevant to the goals of the PLUS Consortium are also encouraged.

Harvard Stem Cell Institute - Request for Applications for Seed Grant Funding ($100,000 award including 20% IDC's, deadline May 15th, 2017).  Harvard Stem Cell Institute (HSCI) invites applications for seed grant funding for its 2017 cycle. The purpose of this program is to provide funding for innovative projects in the field of stem cell and regenerative biology. As was the case last year, HSCI strongly encourages proposals with a translational focus, or which are otherwise poised to accelerate the development of new stem cell-based therapies or cures. However, proposals at all stages of development are welcome. HSCI intends to award up to ten grants in response to this request for proposals, contingent upon the number and quality of the proposals received, as well as the availability of HSCI funds. All investigators working in the field of stem cell and regenerative biology are welcome to apply. Junior investigators, and senior investigators from outside the field of stem cell and regenerative biology, are especially encouraged to apply. As part of the application process, applicants will be asked to determine whether their proposal is either basic or translational science. In determining whether a proposal falls into either the basic or translational science category, please consider the aim(s) of your proposal. In general, proposals that fall into the category of translational science are those which aim at: Producing new therapies and/or therapeutic products (e.g. cellular products, large/small molecules, biomaterials, etc.), or Discovering the mechanisms, pathways, or models underlying such therapies/therapeutic products, or Manufacturing and testing stem cell-based therapies and therapeutic products using studies designed to fulfill all applicable institutional, state, and federal regulatory requirements.  Any seed grants awarded during this cycle will be funded at up to $50,000 in total costs (including indirect costs, maximum 20% of total direct costs-basis) per year, for a period not to exceed two years. Basic science proposals will not be reviewed separately from proposals categorized as translational science. All proposals will be reviewed by the HSCI Executive Committee. HSCI reserves the right to not award any seed grants in the 2017 cycle.